Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry

 

 

Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Assoc. Prof. Dr. Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Associate Professor of Pharmacognosy from Deraya university, Egypt

Dr. Eman Maher Zahran is a distinguished academic and researcher in the field of pharmacognosy, currently serving as an Associate Professor at Deraya University’s Faculty of Pharmacy. With a career rooted in natural product research, her work spans the morphological study of medicinal plants to the biological activities of phytoconstituents. A Ph.D. graduate from Minia University, she has demonstrated unwavering commitment to academic excellence, scientific innovation, and student mentorship. Her research integrates traditional knowledge with advanced technologies such as metabolomic profiling, ESI-HR-MS analysis, and molecular docking. Dr. Zahran has authored over 25 impactful peer-reviewed articles and delivered talks at key international and national pharmaceutical conferences. In addition to her scholarly contributions, she is actively involved in student-centered initiatives, scientific committees, and governmental outreach programs. Her editorial and peer-review work across several international journals further amplifies her impact within the global scientific community. A strong advocate for female leadership in science, she completed the prestigious “The Woman Leads” program at Egypt’s National Training Academy. Dr. Zahran’s blend of academic excellence, innovative research, leadership in community engagement, and dedication to advancing pharmacognosy education positions her as a leading figure in Egypt’s pharmaceutical sciences landscape.

Professional Profile

Education

Dr. Eman Maher Zahran’s educational journey is deeply rooted in Minia University, where she pursued her undergraduate, master’s, and doctoral degrees in Pharmaceutical Sciences with a specialization in Pharmacognosy. She completed her B.Sc. in Pharmaceutical Sciences in 2006 with a cumulative grade of “Very Good.” Her keen interest in medicinal plants and natural product research led her to undertake pre-master courses in 2007, which served as the foundation for her M.Sc. that spanned from 2007 to 2013. Her master’s research involved the detailed phytochemical investigation of plant constituents and their pharmacological evaluation. From 2016 to 2020, she pursued her Ph.D. at the Faculty of Pharmacy, Minia University, where she delved into advanced areas such as metabolomics, molecular docking, and structure elucidation of phytoconstituents. Her doctoral work not only reflected technical expertise but also interdisciplinary collaboration. During this academic trajectory, she also completed specialized training programs and participated in scientific workshops that refined her methodological capabilities. The strength of her education lies in its comprehensive nature, encompassing foundational knowledge, research techniques, and a critical understanding of the pharmacological potential of natural compounds, all of which have laid the groundwork for her ongoing contributions to pharmaceutical research and academia.

Professional Experience

Dr. Zahran’s professional trajectory reflects a steady and strategic ascent through the academic ranks of pharmacognosy. She began her journey as a community pharmacist, transitioning into academia in 2008 as a postgraduate researcher and then as a teaching assistant. Between 2010 and 2012, she served as a grant teaching assistant for Clinical Pharmacy students. From 2016 to 2020, she was appointed Associate Lecturer at the Faculty of Pharmacy, Minia University. In 2020, she was promoted to Assistant Professor, where she continued to lead educational initiatives, mentor students, and develop curricula. As of March 2025, she holds the rank of Associate Professor at Deraya University. Dr. Zahran has also been deeply involved in co-curricular activities, supervising multiple student-led initiatives such as “Hayah,” a student entity focused on scientific and community outreach. She has contributed to post-graduate course development and served on Deraya’s Quality Assurance and Accreditation Unit. Her participation in national-level training programs like “The Woman Leads” demonstrates her leadership and civic engagement. With over 15 years of diverse experience spanning pharmacy practice, teaching, and research, Dr. Zahran has emerged as a dynamic academic professional, recognized for her commitment to excellence, innovation, and interdisciplinary collaboration.

Research Interests

Dr. Zahran’s research interests center on pharmacognosy and natural product chemistry, with a strong emphasis on isolating, identifying, and evaluating bioactive phytoconstituents derived from medicinal plants and marine algae. Her work integrates classical botanical techniques with cutting-edge technologies like ESI-HR-MS analysis and molecular docking. A unique aspect of her research involves the application of network pharmacology to uncover the multi-target mechanisms of natural compounds, especially in treating complex disorders like ADHD and osteoarthritis. Her contributions extend to investigating the wound healing, antifungal, antiplasmodial, and anti-inflammatory properties of various natural substances. Recently, she has delved into combining natural phytochemicals with stem cell therapies to enhance regenerative medicine applications. Additionally, Dr. Zahran’s studies examine the environmental and biochemical effects of phytoconstituents using in vitro, in vivo, and in silico models. This holistic and multidisciplinary approach allows her to bridge the gap between traditional herbal medicine and contemporary pharmacological science. Her interest in neuropsychiatric disorders also reflects a forward-thinking orientation, exploring novel therapeutic avenues. Through her robust pipeline of projects and publications, she continues to identify plant-based compounds with the potential to be developed into pharmaceutical agents, contributing significantly to both academic knowledge and practical healthcare innovation.

Research Skills

Dr. Eman Maher Zahran is equipped with an extensive set of research skills that make her a leading expert in pharmacognosy and natural product research. She is proficient in the morphological and micromorphological analysis of medicinal plants and marine algae, with deep expertise in isolation and structure elucidation techniques for phytochemicals. Her methodological proficiency spans thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and advanced mass spectrometric techniques, including ESI-HR-MS. Furthermore, she demonstrates high competence in molecular docking, network pharmacology, and in silico ADME studies, which she integrates seamlessly into phytochemical investigations. Dr. Zahran is also skilled in conducting both in vitro and in vivo biological activity assessments, exploring pharmacodynamics and pharmacokinetics of bioactive compounds. Her research frequently employs interdisciplinary approaches, such as combining plant extracts with mesenchymal stem cells in regenerative medicine models. Additionally, she is adept in scientific writing and publishing, having authored numerous high-impact papers in Scopus-indexed and Web of Science journals. Her peer-review activities and editorial board membership further reflect her critical appraisal capabilities. Collectively, her skills not only underscore her technical competence but also her innovative spirit and dedication to producing translational research that advances healthcare through natural product pharmacology.

Awards and Honors

Dr. Eman Maher Zahran has garnered significant recognition for her academic achievements, both within her institution and the broader scientific community. She was honored by Deraya University for her outstanding academic contributions from 2020 onward, a period during which she published prolifically and advanced numerous research projects. Her active role in student development and community outreach, particularly through her supervision of the “Hayah” entity and ADHD-focused conferences, highlights her multifaceted impact. In 2023, she was selected to join the second cohort of the Egyptian National Training Academy’s “The Woman Leads” program, which is designed to empower and equip promising female leaders in science and education. She serves as an editorial board member and peer reviewer for multiple prestigious journals, including the Journal of Pharmaceutical Chemistry & Chemical Science, Octahedron Drug Research, and journals by the Royal Society of Chemistry. Furthermore, her selection to the scientific committee of international congresses on nanoscience and pharmacology reflects her expertise and respected standing in the academic community. These honors not only affirm her scientific merit but also her leadership, dedication to knowledge dissemination, and her influential role in shaping the future of pharmacognosy in Egypt and beyond.

Conclusion

Dr. Eman Maher Zahran exemplifies the qualities of a dedicated academic, an innovative researcher, and an inspiring mentor. Her career is marked by a relentless pursuit of excellence, from foundational studies in pharmaceutical sciences to cutting-edge research in natural product pharmacology. Her interdisciplinary focus—combining phytochemistry, molecular modeling, and regenerative medicine—demonstrates her commitment to translating traditional medicinal knowledge into therapeutic breakthroughs. Dr. Zahran’s engagement with students, leadership in research committees, and active role in scientific communication reflect her holistic academic persona. Her prolific publication record, participation in international conferences, and collaborations underscore her relevance on both national and global levels. Equally commendable is her devotion to community-based initiatives, particularly in raising awareness and support for neuropsychiatric conditions like ADHD. Her recognition through institutional awards and national leadership programs stands as a testament to her impact. As she continues to expand her research footprint and inspire the next generation of scientists, Dr. Zahran remains a vital force in the advancement of pharmacognosy and pharmaceutical sciences. Her contributions resonate far beyond the laboratory and classroom, positioning her as a role model and a key influencer in the evolving landscape of academic research and community health promotion.

Publications Top Notes

  • Title: Diversity, phytochemical and medicinal potential of the genus Ocimum L. (Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, HE Khalil, SY Desoukey, MA Fouad, …
    Year: 2020
    Citations: 86

  • Title: Bioactivity potential of marine natural products from scleractinia-associated microbes and in silico anti-SARS-COV-2 evaluation
    Authors: EM Zahran, A Albohy, A Khalil, AH Ibrahim, HA Ahmed, EM El-Hossary, …
    Year: 2020
    Citations: 41

  • Title: Antioxidant and wound healing potential of Vitis vinifera seeds supported by phytochemical characterization and docking studies
    Authors: T Al-Warhi, EM Zahran, S Selim, MM Al-Sanea, MM Ghoneim, SA Maher, …
    Year: 2022
    Citations: 36

  • Title: Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
    Authors: A Albohy, EM Zahran, UR Abdelmohsen, MA Salem, T Al-Warhi, …
    Year: 2022
    Citations: 29

  • Title: Antiulcer potential and molecular docking of flavonoids from Ocimum forskolei Benth., family Lamiaceae
    Authors: EM Zahran, UR Abdelmohsen, AS Hussein, MA Salem, HE Khalil, …
    Year: 2021
    Citations: 27

  • Title: Scabicidal potential of coconut seed extract in rabbits via downregulating inflammatory/immune cross talk: A comprehensive phytochemical/GC-MS and in silico proof
    Authors: EM Zahran, NMR Abdel-Maqsoud, OY Tammam, IM Abdel-Rahman, …
    Year: 2022
    Citations: 23

  • Title: New Acaciin-loaded self-assembled nanofibers as MPro inhibitors against BCV as a surrogate model for SARS-CoV-2
    Authors: SA Mohamad, EM Zahran, MR Abdel Fadeel, A Albohy, MA Safwat
    Year: 2021
    Citations: 23

  • Title: New halogenated compounds from Halimeda macroloba seaweed with potential inhibitory activity against malaria
    Authors: AH Elmaidomy, EM Zahran, R Soltane, A Alasiri, H Saber, CJ Ngwa, …
    Year: 2022
    Citations: 22

  • Title: Metabolic profiling, histopathological anti-ulcer study, molecular docking and molecular dynamics of ursolic acid isolated from Ocimum forskolei Benth. (family Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, AT Ayoub, MA Salem, HE Khalil, …
    Year: 2020
    Citations: 21

  • Title: Cytotoxic and anti-diabetic potential, metabolic profiling and in silico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
    Authors: SS Eldin Elhawary, AE Elmotayam, D Alsayed, EM Zahran, MA Fouad, …
    Year: 2022
    Citations: 11

Na Zhang | Pharmaceutical Science | Best Researcher Award

Prof. Na Zhang | Pharmaceutical Science | Best Researcher Award

Shandong university, China.

Dr. Na Zhang is a distinguished professor at the Institute of Pharmaceutics, Shandong University, China. She earned her Ph.D. in Pharmaceutics from China Pharmaceutical University in July 2004, following her Master’s and Bachelor’s degrees in Pharmacy from Shandong Medical University. Over her extensive career, Dr. Zhang has made significant contributions to the field of pharmaceutics, focusing on innovative drug delivery systems and cancer therapies. With over two decades of academic and research experience, she has established herself as a leader in her field, exemplified by her role as Associate Dean of the School of Pharmaceutical Science. Dr. Zhang’s research has garnered international recognition through numerous publications in high-impact journals, collaborative projects, and successful funding grants. She is dedicated to advancing pharmaceutical education while actively engaging in cutting-edge research that addresses critical healthcare challenges.

Professional Profile

Education

Dr. Na Zhang completed her Ph.D. in Pharmaceutics at the School of Pharmacy, China Pharmaceutical University, in July 2004. Prior to that, she obtained her Master’s degree in Pharmacy in July 1995 from Shandong Medical University, and her Bachelor’s degree in Pharmacy from the same institution in July 1992. Her educational journey has laid a solid foundation for her expertise in pharmaceutics, equipping her with the knowledge and skills to excel in both research and academic settings. Throughout her studies, Dr. Zhang has consistently demonstrated a commitment to academic excellence and innovation, which is evident in her subsequent professional achievements. Her comprehensive educational background enables her to contribute significantly to the fields of drug delivery systems and cancer immunotherapy, fostering the development of advanced pharmaceutical solutions that address pressing health issues.

Professional Experience

Dr. Na Zhang has a robust professional background spanning over two decades in academia and research. Since January 2013, she has served as a professor and Associate Dean at the School of Pharmaceutical Science, Shandong University. Prior to this, she held various positions, including Associate Professor and lecturer at Shandong University and a postdoctoral fellowship at the University of Kansas. Dr. Zhang’s career trajectory illustrates her dedication to the advancement of pharmaceutical sciences through teaching, research, and leadership. Her roles have involved mentoring students and researchers, developing curricula, and contributing to institutional governance. Dr. Zhang’s extensive experience in academia enables her to bridge the gap between scientific research and education, ensuring that her students are well-prepared for future challenges in the pharmaceutical industry.

Research Interests

Dr. Na Zhang’s research interests encompass a wide range of areas within pharmaceutics, particularly focusing on innovative drug delivery systems. She specializes in nano-drug delivery systems, exploring stimuli-responsive carriers for targeted therapy, and cancer immunotherapy. Her work on small molecule-based nanodrugs aims to enhance the efficacy and safety of cancer treatments, addressing critical challenges in current therapeutic approaches. Additionally, she engages in pre-clinical biopharmaceutical evaluation to assess the pharmacokinetics and dynamics of her developed formulations. By combining her expertise in nanotechnology and pharmaceutical sciences, Dr. Zhang seeks to contribute significantly to the field, improving treatment outcomes for patients with cancer and other complex diseases.

Research Skills

Dr. Na Zhang possesses a diverse array of research skills that enhance her effectiveness as a scientist and educator. Her expertise includes the design and development of nano-drug delivery systems, with a particular focus on creating stimuli-responsive carriers. She is proficient in pre-clinical biopharmaceutical evaluation, which involves assessing the pharmacological and therapeutic properties of new drug formulations. Additionally, Dr. Zhang has extensive experience in experimental design, data analysis, and scientific writing, which are essential for conducting high-quality research and publishing in reputable journals. Her collaborative approach fosters interdisciplinary partnerships, enhancing her research’s impact and relevance. Furthermore, her leadership in academic settings enables her to mentor aspiring researchers, sharing her knowledge and skills to cultivate the next generation of pharmaceutical scientists.

Awards and Honors

Dr. Na Zhang’s outstanding contributions to pharmaceutical sciences have earned her numerous awards and honors throughout her career. She has been recognized for her innovative research in nano-drug delivery and cancer immunotherapy, reflecting her commitment to advancing healthcare solutions. Her research has garnered prestigious funding from national bodies, highlighting the significance of her work in the field. Furthermore, Dr. Zhang has received accolades for her excellence in teaching and mentoring, demonstrating her dedication to fostering academic growth among her students. As a published author in high-impact journals, she has received recognition from peers and the broader scientific community for her contributions to advancing pharmaceutical knowledge. Her achievements underscore her influence as a researcher and educator in the pharmaceutical sciences.

Conclusion:

Dr. Na Zhang stands out as an exemplary candidate for the Best Researcher Award due to her significant contributions to pharmaceutical sciences, particularly in nano-drug delivery and cancer immunotherapy. Her impressive publication record, successful acquisition of research funding, and commitment to education reflect her dedication and impact in the field. By addressing the areas for improvement, Dr. Zhang can further enhance her influence and leadership within the global research community. Thus, she is highly deserving of this recognition.

Publications Top Notes

  1. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours
    • Authors: Liu, J., Zhao, H., Gao, T., Zhang, N., Liu, Y.
    • Year: 2024
  2. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
    • Authors: Yang, H., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2024
  3. Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems
    • Authors: Liu, J., Liu, J., Mu, W., Liu, Y., Zhang, N.
    • Year: 2024
    • Citations: 1
  4. In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency
    • Authors: Gao, T., Yuan, S., Liang, S., Zhang, N., Liu, Y.
    • Year: 2024
  5. Nano-Regulator Inhibits Tumor Immune Escape via the “Two-Way Regulation” Epigenetic Therapy Strategy
    • Authors: Liang, S., Liu, M., Mu, W., Jiang, D., Zhang, N.
    • Year: 2024
    • Citations: 3
  6. Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy
    • Authors: Xia, Z., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 2
  7. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy
    • Authors: Xia, Y., Fu, S., Ma, Q., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 30
  8. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling
    • Authors: Fu, S., Chang, L., Liu, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 32
  9. Corrigendum to “In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy”
    • Authors: Zhang, Z., Liang, S., Fu, S., Liu, Y., Zhang, N.
    • Year: 2023
  10. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
  • Authors: Gao, T., Sang, X., Huang, X., Liu, Y., Zhang, N.
  • Year: 2023
  • Citations: 3